Aytu BioPharma (NASDAQ:AYTU) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.17) by 223.53 percent. This is a 140.38 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $18.45 million which beat the analyst consensus estimate of $13.74 million by 34.30 percent. This is a 31.57 percent increase over sales of $14.03 million the same period last year.